This site is intended for health professionals only
Thursday 23 May 2019
Share |

Amylin seeks approval for diabetes jab

Amylin Pharmaceuticals is seeking approval from the Food and Drug Administration (FDA) for its once-weekly injectable diabetes treatment.

The biotechnology company's exenatide LAR is a new version of the twice-daily injectable drug Byetta, which is used to control blood sugar levels.

According to Wall Street, getting approval for the highly anticipated drug has the potential to reinvigorate sales for Amylin, and the drug is seen as commercially advantageous because it requires a much lower dose than previous treatments.

Competition for exenatide LAR includes Novo Nordisk's once-daily injection liraglutide, which is currently under FDA review.

Both exenatide LAR and liraglutide help increase the body's insulin production and are part of the GLP-1 analogues class of diabetes treatments.

Companies developing diabetes treatments must follow new safety guidelines issued by the FDA, which came into force after concerns about heightened risks of heart attack with GlaxoSmithKline's blockbuster pill Avandia.

Copyright Press Association 2009

Amylin Pharmaceuticals

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher